Check Point Software Stock Price Target Lowered to $220 by Cantor Fitzgerald Cantor Fitzgerald analysts have reduced their price target for Check Point Software Technologies (CHKP) to $220, signaling a...
Stifel Trims Etsy Price Target, Maintaining Hold Rating Stifel analysts have lowered their price target for Etsy (ETSY) stock to $64 from $66, while maintaining a “Hold” rating. This slight...
Stifel Slashes Dyne Therapeutics Price Target Amidst Endpoint Changes Stifel has significantly lowered its price target for Dyne Therapeutics (DYN) to $36, reflecting adjustments to the company’s clinical trial endpoints....
Stifel Raises OneSpaWorld Price Target to $25 on Margin Improvement Stifel has raised its price target for OneSpaWorld (OSW) stock to $25, citing improving margins. This represents a significant increase...
BofA Securities Boosts Altria Price Target to $64, Citing Resilient Operations BofA Securities has raised its price target for Altria stock to $64, highlighting the company’s robust performance despite ongoing...
Morgan Stanley Upgrades Ionis Pharmaceuticals on Strong Tryngolza Launch Morgan Stanley has upgraded Ionis Pharmaceuticals stock, signaling increased confidence in the company’s future prospects following the successful launch of its...
Oppenheimer Lowers UnitedHealth Price Target, Signaling Reset Expectations Oppenheimer analysts have lowered their price target for UnitedHealth Group (UNH) to $325, indicating a recalibration of expectations for the healthcare giant....
Boeing Stock Soars After Bernstein Raises Price Target to $287 on Strong Q2 Results Boeing’s stock price received a significant boost after Bernstein Research raised its price target to $287,...
Bernstein Boosts Alnylam’s Price Target on Promising Amvuttra Outlook Alnylam Pharmaceuticals received a vote of confidence from Bernstein, with the investment firm raising its price target on the biotech company’s...
Bernstein Boosts Sarepta Therapeutics Price Target to $18 Following Elevidys Approval Bernstein has raised its price target for Sarepta Therapeutics stock to $18 from a previous level, following the FDA’s...
